Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

LBT-999

Phase 2Small molecule

IInstitut National de la Santé Et de la Recherche Médicale, France

LBT-999 is one of 8 small molecule programs targeting Biomarkers. It is currently in Phase 2.

1

Indications

1

Total Trials

1

Active Trials

7

Competitors

Pipeline

Status by Indication[3][1]

Indication

BiomarkersRecruiting

BiomarkersPhase 2

Recruiting

Competition

Competitive Landscape

9 competitors in Biomarkers

#DrugCompanyPhaseTrials

Kerendia

Ozempic

Attruby

NNavire Pharma Inc., a BridgeBio company

Aldara

BBausch Health Americas, Inc.

Secretin-Ferring

Standard Treatment

Boehringer Ingelheim

LBT-999

IInstitut National de la Santé Et de la Recherche Médicale, France

Nicotine Lozenge

FFertin Pharma A/S

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Recruiting

Biomarkers

NCT06930261

Clinical

Trials by Indication[1]

Biomarkers1 trial

Dopaminergic Disruption Induced by Traumatic Coma: Dopaminergic Pathways Abnormalities and Biomarkers of Recovery Using MRI and 18F-LBT-999 PET

Recruiting·IInstitut National de la Santé Et de la Recherche Médicale, France·Phase 2·NCT06930261·55 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for LBT-999. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LBT-999 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LBT-999. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institut National de la Santé Et de la Recherche Médicale, France company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IInstitut National de la Santé Et de la Recherche Médicale, France

Related News